Mesoblast Archives

Hoping for approval, Mesoblast says FDA wants new remestemcel-L trial

August 3, 2023 / Professor Paul Knoepfler, Ph.D. / 1 Comment

Australian biotech Mesoblast has had a rollercoaster ride working toward FDA approval of its mesenchymal cell therapy product remestemcel-L. They are seeking approval for use in patients with graft-versus-host disease (GvHD). More specifically, it is intended for pediatric patients with steroid-refractory acute graft versus host disease, or SR-aGVHD. This is a serious condition and new treatment […]

Hoping for approval, Mesoblast says FDA wants new remestemcel-L trial Read More »

Recommended reads: MSCs, vision, endothelial cells, more

January 3, 2021 / Professor Paul Knoepfler, Ph.D. / Leave a Comment

What a year 2020 was, but there was still plenty of great science, which continues now in 2021 including published research like today’s recommended pieces and there’s one thread on MSCs today. The Niche new look, more features, and a Medical Advisory Board for 2021 Before we get to the recommended reads, note that 2021

Mesoblast stock hit on gloomy data on stem cells for COVID-19

December 22, 2020 / Professor Paul Knoepfler, Ph.D. / 3 Comments

I’ve been closely following the arena of stem cells for COVID-19 since the pandemic broke including the efforts of Mesoblast. Mesoblast unlikely to meet primary endpoints in Phase III COVID trial Now, the firm got bad news as its DSMB reported that they are unlikely to meet the primary endpoint for their Phase III trial

Mesoblast stock hit on gloomy data on stem cells for COVID-19 Read More »

Mesoblast

Hoping for approval, Mesoblast says FDA wants new remestemcel-L trial

Recommended reads: MSCs, vision, endothelial cells, more

Mesoblast stock hit on gloomy data on stem cells for COVID-19

Subscribe to Our Newsletter